Would you believe another snow day in Louisiana, which is number three in the past couple of weeks (if you were counting). In general, despite a very weak market , biotechs did fairly well, although it was the large caps holding up the sector with the small caps more mixed. It was nice to see […]
January 27 Biotech Update
It is amazing how quickly sentiment can change. Last week I was noting the shifts and the expectations for a correction. This was certainly needed but I think the speed of the move has less to do with fundamentals and more to do with jittery investors. Nobody wants to be the last one to sell, […]
January 10 Biotech Update- The Revenge of Momentum
Another busy day in the market. It seems like the small caps want to steal the show and perhaps we will see the large caps take the next leg higher with their presentations next week. I have been saying for awhile that JPM would be a tell for the sector and while the conference has […]
A look at Innate Pharma
Immuno-oncology was one of the hottest themes of 2013 and its been almost entirely a big pharma story. We saw Bristol-Myers Squibb, Merck and Roche reveal more data and future plans for their PD-1 and PD-L1 inhibitors. It’s going to be the hottest theme for awhile, so we want to highlight one company that has […]
December 20 Biotech Update- Wrapping up the Year
It was a good day for the market and biotechs were strong once again. It seems like tax loss selling is winding down and selling volume is starting to dry up. So we are likely to have a positive bias for the rest of the year. It also helps that the news flow in biotechs […]
December 18 Daily Biotech Update- A Couple of Surprises
Well, the taper was exactly what the market and biotech sector need. Who saw that one coming? Is this simply a relief rally, start of a Santa rally, or setting us up for a bigger fall? For the biotech sector I see it more as a relief rally at this point but one that may […]
BMY – Quick Chart Update
Bristol-Myers Squibb Company (BMY) -NYSE Interesting price action since September 9th after breaking out the downtrend line around $41.90, we kept watching the chart day after day during the preparation to AASLD reaching the high of $47.90, followed by a price consolidation and forming a flag pattern that we discussed several times through the private […]
November 22 Biotech Update- A Busy CHMP out with some Bullish News
You will notice that I am change the title to something more descriptive, hopefully you will still read the updates with this change. Sentiment is certainly shifting in the biotech sector and it seems to be doing so as quickly as it turned negative. What was my fear that the sector would be hit with […]
ASH 2013 Preview on Multiple Myeloma
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs on the backs of Pharmacyclic’s Ibrutinib (stock is up 1000% since ASH11), Celgene’s Revlimid (~67% of their $6.3B 2013 revenue) and Amgen’s $10.6B deal for […]
CLDX – A look at CDX-1127
Celldex Therapeutics (CLDX) has one of the most anticipated data releases amongst small biotech companies this fall. They are scheduled to present data from their Phase 1 dose-escalation trial of a CDX-1127 (CD27, a T-cell stimulator) at the annual meeting of the Society for ImmunoTherapy of Cancer(SITC), November 7-10th. We will also likely see some […]
October 29- EOD
Well, it seemed like an odd day for the sector in that it was almost directionless. This is not to say that there were not moves among individual stocks but we are finally starting to see them move on merit and less on sector sentiment. I think this is a good sign and hopefully we […]
Datasets in focus at IASLC this weekend
This weekend is the 15th annual World Conference on Lung Cancer, sponsored by tge International Assoc. for The Study Of Lung Cancer (IASLC). It takes place Sunday October 27th through Wednesday 30th (Site). Abstracts can be found here. In particular, we want to speak briefly about 7 presentations. PD1 inhibitors Bristol-Myers (BMY), Merck (MRK) and Roche (RHHBY) […]
October 23-EOD
Not a lot of news in terms of data, although we saw BMY, AMGN, and LLY report earnings. The biotech sector was not as much of a relative underperformer today. Of course, it was still red and weak but today it was red and weak in the context of a broader market selloff. Volumes seemed […]
October 1- EOD
It was a fairly busy day today in biotech land the sentiment certainly appears more positive. They participated in the market rally even though most were not big losers in the recent macro selling. This is certainly positive going forward. I want to focus on the MRK news as it touches on a lot of […]
September 27- EOD
Not a particularly news rich day but the sector seemed to continue its momentum from yesterday and seemed to outperform the general market with a lot of green on a red day. 1. Well, it looks like JNJ is tossing another wrench in ECYT trials with more doxil supply problems. ECYT noted that they have […]
Upcoming Fall medical conferences
With Fall approaching quickly, we head into one of the busier periods of medical conference presentations. In the next month, we have several widely followed conferences approaching and abstract releases for a number of others. Below are some of the key conferences that we will be tracking with some analysis to follow in subsequent articles. […]
July 16- EOD
Seemed like a slow news day as the markets pulled back to consolidate some of the recent moves. Biotechs were not immune to the move, although some clearly performed better than others. 1. EPZM has shown incredible strength since the IPO. While I like this company’s technology and would like to own some shares, it […]
July 1- EOD
Today was the fallout of the AMGN bid for ONXX. There are a couple of aspects of it that I want to touch on and go a little further than my article this morning. 1. In my article I tried to cover the companies that I thought had the most compelling reasons to be interested […]
BMY – In A Consolidation Mode
Bristol-Myers Squibb Company (NYSE: BMY) BMY had an amazing run ahead of ASCO-2013 that left many well-planned traders very happy. The stock found strong support near the 50-Day Moving Average around $39.50 where many traders(ourselves included) started initial positions. The stock had a great run into the ASCO abstracts release on May 15th, moving roughly […]
ABBV – A look into Abbvie
with Patrick Crutcher and Jason Chew Abbvie (ABBV) presented data on its oncology candidates at ASCO meeting and updated investors at Jefferies Healthcare Conference last week. The stock, like other fellow big caps, has had a considerable run over the past few months and is up 25% YTD, after the split from Abbott (ABT). On […]